Prophylaxis and therapy of aphakic cystoid macular edema

Jampol, Lee M.; Sanders, Donald R.; Kraff, Manus C.

doi:10.1016/0039-6257(84)90237-6

Cited by 49 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…49 However, the overall rate of CME in this study (2.4%) was not higher than previously reported rates for surgeries performed by attending physicians. 47,50 Also, the benefit of the higher intraoperative complication rate in resident surgery allowed us to evaluate a larger number of patients in this high-risk category.…”

Section: Discussionmentioning

confidence: 99%

Clinical pseudophakic cystoid macular edema

Henderson¹,

Kim²,

Ament³

et al. 2007

Journal of Cataract and Refractive Surgery

268

105

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical pseudophakic cystoid macular edema

Henderson¹,

Kim²,

Ament³

et al. 2007

Journal of Cataract and Refractive Surgery

268

105

View full text Add to dashboard Cite

show abstract

“…rectomy) occurs in about 1% [1][2][3] , despite improved surgical techniques, and may lead to a permanent decrease in visual acuity. In the pathogenesis of the cystoid macular edema, increased inflammatory markers such as prostaglandins E2 [4] and cytokines like IL-1β or CCL2 [5] are discussed.…”

mentioning

confidence: 99%

Intravitreal Dexamethasone Implant for the Treatment of Postoperative Macular Edema

Klamann¹,

Böttcher²,

Ackermann³

et al. 2016

Ophthalmologica

View full text Add to dashboard Cite

Introduction: Macular edema after cataract surgery (Irvine-Gass syndrome) or pars plana vitrectomy is a postoperative complication which can lead to permanent visual loss. Increased inflammatory substances, such as prostaglandins and cytokines, are discussed to be causative. Currently, there are no evidence-based guidelines for the treatment of postoperative macular edema. Intravitreal dexamethasone (DEX) could be effective by its anti-inflammatory effect. We examined the functional and morphological results of treatment with 0.7 mg intravitreal DEX implant (Ozurdex®). Methods: In an observational study, we analyzed visual acuity (logMAR), intraocular pressure (IOP), clinical findings, and the central macular thickness (CMT, optical coherence tomography [OCT] Spectralis®, Heidelberg Engineering, 30° macular scan, 19 scans) of 12 eyes before and 1 month after the last DEX implantation (off-label use, Ozurdex®, Allergan, Inc., Irvine, CA, USA) for macular edema after cataract surgery or vitrectomy. Re-implantation was performed when OCT showed new intraretinal fluid along with a decrease in the patient's visual acuity. The mean follow-up was 14.4 ± 10.6 months. Results: Twelve eyes of 12 patients (4 female, 8 male) with a mean age of 62.6 ± 11.9 years were treated with a mean of 2.5 ± 1.6 intravitreal DEX implant injections. Prior to injection, the visual acuity was 0.74 ± 0.34 logMAR and the CMT was 608 ± 129 µm. One month after the last injection (after a mean of 437 ± 322 days), the CMT normalized (300 ± 90 µm, p < 0.01) in all cases with a visual acuity of 0.49 ± 0.43 logMAR (p < 0.01). After 8.1 ± 5.3 months, recurring macular edema could be completely reduced by re-injection in 66% (8 patients). Four patients had no recurrence. Postinjection, the mean IOP was 17.4 ± 6.8 mm Hg. Postinjection, 7 patients required topical antiglaucomatous therapy. Conclusions: Treatment with an intravitreal DEX implant is an effective therapy for postoperative macular edema. Each injection leads to a complete resorption of the edema with a significant increase in visual acuity.

show abstract

“…In our study, all patients were treated according to a standardized protocol established at the Institute of Ophthalmology, Catholic University ''Sacro Cuore-Policlinico A. Gemelli,'' Rome. However, several therapeutic choices have been suggested for the management of PCME, 5,12,[30][31][32][33][34] and there is not yet a general consensus among different proposals for the prevention or treatment of PCME. Assessment of the efficacy of the used therapeutic protocol was beyond the scope of this study, which aimed at evaluating the clinical use of SD-OCT in PCME.…”

Section: Discussionmentioning

confidence: 98%